{"entity":{"id":"nct06679634","kind":"trial","name":"Retinoblastoma Phase II Expanded Access Clinical Trial","aka":[],"tldr":"A phase 2 trial of Topotecan in retinoblastoma, run by Targeted Therapy Technologies, LLC, now recruiting.","summary":"Retinoblastoma Phase II Expanded Access Clinical Trial is a phase 2 interventional study registered as NCT06679634 by Targeted Therapy Technologies, LLC, with 30 participants planned, started 2025-02-21 and due to reach its primary completion in 2029-11. Interventions recorded: Chemoplaque also referred to as Episcleral Topotecan.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06679634","url":"https://clinicaltrials.gov/study/NCT06679634"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["retinoblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["topotecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06679634","phase":"2","setting":"Retinoblastoma Phase II Expanded Access Clinical Trial","sponsor":"Targeted Therapy Technologies, LLC","enrolled":30,"outcomes":[]},"route":"/trials/nct06679634/","neighbours":{"cancer":[{"id":"retinoblastoma","kind":"cancer","name":"Retinoblastoma","route":"/cancers/retinoblastoma/"}],"drug":[{"id":"topotecan","kind":"drug","name":"Topotecan","route":"/drugs/topotecan/"}]}}